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?To reduce drug costs for persons admitted to welfare facilities for the elderly requiring long-term care (WFEC) who have been 
taking antihypertensive drugs, pharmacists helped doctors change the prescription. Pharmacists performed physical assessment of 
patients as a part of drug safety management. The pharmacists proposed to the doctors that incoming patients switch 1) from Angio-
tensin II type 1 Receptor Blockers (ARB) to the generic angiotensin-converting enzyme inhibitors (ACEI) and 2) from brand name 
antihypertensive drugs other than ARB (AHD) to generic drugs. The doctors agreed with the pharmacists, and the prescriptions were 
changed. For patients who had taken AHD, no significant differences were observed in blood pressure by switching to the generic 
drug. Alternatively, although it was possible to maintain BP up to less than 140/90 mmHg by switching from ARB to ACEI, two 
thirds of patients had increased blood pressure. One patient experienced an uncomfortable feeling in the throat and another developed 
an itchy rash, but these symptoms disappeared within two weeks. For 14 patients over 30 days, drug costs were reduced approxi-
mately 40,000 yen. In this study, an additional role for pharmacists at WFEC was proposed.
(J Community Pharm Pharm Sci 2011; 3: 39–44)
